Gentris Diagnostics

Gentris is a leading provider of pharmacogenomics (PGx) and companion diagnostic (CDx) services, specializing in the application of genomic technologies to improve drug development and patient care. Founded in 2001 and headquartered in Morrisville, North Carolina, the company offers a comprehensive suite of services including DNA/RNA extraction, genotyping, gene expression analysis, and bioinformatics. Gentris supports pharmaceutical and biotechnology companies throughout the clinical trial process by identifying genetic biomarkers that predict drug response, safety, and efficacy. The company was acquired by Cancer Genetics, Inc. in 2014, and its clinical operations were later transitioned to Interpace Biosciences. Its expertise spans across multiple therapeutic areas, with a strong focus on oncology and personalized medicine.